Back to the Top
The following message was posted to: PharmPK
Dear J Aguirre,
We have perfomed trials with oral bisphosphonate formulations, including
alendronate. Just let me know which is the exact point you will like to
discuss I may be able to provide non-confidential information.
Emilio Roldán, MD, PhD
Bisphosphonate Project Leader
Gador SA
Degrossi OJ, Ortiz M, Degrossi EB, Garcia del Rio H, Barreira JC,
Messina D,
Kerzberg E, Roldán EJA, Montuori E, Perez Lloret A. Bone scanning, serum
kinetics and bioavailability of 99m Tc sodium olpadronate in patients
with
different bone turnover. Eur J Clin Pharmacol, 48 (6): 489-494, 1995.
Araujo G, Quattrocchi O, Plotkin H, Zanchetta JR, Piccinni E, Roldán E.
Bioequivalence between enteric-coated pamidronate capsules and tablets.
A
cross-over trial in healthy volunteers. Procc. VI World Conference on
Clinical Pharmacology and Therapeutics, Buenos Aires, 4 al 9 de Agosto
de
1996. Acta Physiol Pharmacol et Therap Latino Am 46 (6): 275, 1996.
(abstract)
Roldán EJA, Araujo G, Quattrocchi O, Zanetti D, Piccinni E, Perez
Lloret A.
Influence of the particle size of oral pamidronate (APD) on digestive
tolerability. Procc. VI World Conference on Clinical Pharmacology and
Therapeutics, Buenos Aires, 4 al 9 de Agosto de 1996. Acta Physiol
Pharmacol
et Therap Latino Am 46 (6): 274, 1996. (abstract)
Roldán EJA, Quattrocchi O, Araujo G, Piccinni E: Aplicación clínica de
los
principios farmacocinéticos de los bisfosfonatos. Medicina (Buenos
Aires) 57
(supl 1): 76-82, 1997
Roldán EJA, Quattrocchi O, Zanchetta JR, Plotkin H, Araujo G, Piccinni
E.
Comparable bioavailability of two esophago-gastric protective
formulations
containing pamidronate (APD). A cross-over trial in healthy young
adults.
Medicina (Buenos Aires), 62 (4): 317-322, 2002.
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)